Evidence map›Paper›PMID 42270819›Full record

ArticleScientific reports2026

Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study.

Lin Ye, Wanrong Yue, Kangqiang Lin, Jiaye Liao, Ali Mo, Guoxing Liu, Xuanting Chen, Hao Shi, Tao Wang, Qingrong Mo and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lin Ye *Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China. yelin@stu.glmc.edu.cn.
Wanrong Yue *Department of Pathology, Guilin People's Hospital, Guilin, China.
Kangqiang LinDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Jiaye LiaoDepartment of Hepatobiliary Surgery, The Central Hospital of Shaoyang, Shaoyang, China.
Ali MoDepartment of General Surgery, The First Affiliated Hospital of Shaoyang University, Shaoyang, China.
Guoxing LiuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Xuanting ChenDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Hao ShiDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Tao WangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Qingrong MoDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Jun WengDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Yingjie ZhouDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Renjian LiDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Zhao JiangDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China.
Jiguang LuoDepartment of Hepatobiliary Surgery, Bobai County People's Hospital, Guilin, China.
Borong HuangDepartment of Hepatobiliary and Pancreatic Surgery, Nanning No. 9 Peoples Hospital, Nanning, China.
Yaqun YuDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Guilin Medical University, Guilin, China. yyq0129@glmc.edu.cn.

Funding

the Guilin Science Research and Technology Development Project Shike 20230135-1-3The Innovation Project of Guangxi Graduate Education YCBZ2025197
6 · The paper itself

Abstract

Triple therapy combining transarterial chemoembolisation (TACE), tyrosine kinase inhibitors (TKIs), and immune checkpoint inhibitors (ICIs) has shown efficacy in unresectable hepatocellular carcinoma (HCC), but evidence in elderly patients and the role of sarcopenia remain unclear. We enrolled 231 patients aged ≥ 65 years with unresectable HCC who received triple therapy (TACE + TKI + ICI; n = 80) or TACE alone (n = 151) across seven centres in China (2019-2023). Sarcopenia was defined by sex-specific L3 skeletal muscle index (SMI) cutoffs (males: 42 cm

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticImmune Checkpoint InhibitorsLiver NeoplasmsProtein Kinase InhibitorsSarcopeniaAgedAged, 80 and overCombined Modality TherapyFemaleHumansMaleRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsProtein Kinase InhibitorsElderlyHepatocellular carcinomaImmune checkpoint inhibitorsSarcopeniaTransarterial chemoembolisationTriple therapyTyrosine kinase inhibitors

Identifiers

PMID42270819
PMCPMC13500682

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.